Sign In

Jim Howard

CEO, Readout Health (Biosense)

Jim Howard is a seasoned digital health executive with over 27 years of experience. Currently serving as the CEO of Readout Health, a biomarker-based startup, he is known for launching Biosense, a groundbreaking clinical-grade handheld device for measuring nutritional ketosis. Jim's expertise lies in leveraging AI technology for PDT and advancing therapies for chronic diseases and longevity purposes. Prior to Readout Health, he led SentiAR, a company focused on real-time AR platforms for cardiac procedures, securing substantial funding for clinical trials. Jim excels in scaling companies, raising capital, and driving innovation in digital health, software devices, AR/VR, genomics, cardiovascular, and clinical decision support. With a keen interest in global health tech, he is skilled in strategic planning and coaching early-stage CEOs.

Highlights

Jul 20 · linkedin

St. Louis friends, we have a very unique career opportunity for a recent college grad that would thrive in a visionary start up dedicated to changing the trend of chronic diseases related to #nutrition. STL only!

#valuebasedcare #mentalhealth #digitalhealth #diabetes #obesity #MASLD

Jul 10 · linkedin

We can scrutinize payer coverage all day of #GLP -1 drugs. According to this research, 75% stop taking this medication within two years, a medication that is designed to be taken the rest of your life to be effective (in current models).

Since these weight regain prevention drugs, which they are in the current state, are generally not associated with an effective lifestyle modification program program, how could this possibly fit into #valuebasedcare models?

These 75% of patients, almost all of which unfortunately replace their lost lean mass with fat regain to replace that lean mass, are metabolically worse off. NOT good, even if the drug was free.

It is incredibly infrequent that I ever meet anyone that supports endless coverage of this drug class that does not have something personally to gain…

Pharma and #payers do have the opportunity to work with progressive entities that could support an incredibly effective care pathway with this drug class for certain patients, yet align with value-based care realities.

Patient-centric, with all stakeholders winning. Not a moonshot.

Jim Howard
Add to my network

Location

St Louis, Missouri, United States